Topics

Roche Discontinues Duchenne Hope At Interim Analysis

05:22 EST 7 Nov 2019 | SCRIP

Roche is to discontinue its RG6206 clinical development program in Duchenne muscular dystrophy after an interim analysis of the Phase...

      

Related Stories

 

Original Article: Roche Discontinues Duchenne Hope At Interim Analysis

NEXT ARTICLE

More From BioPortfolio on "Roche Discontinues Duchenne Hope At Interim Analysis"

Quick Search

Relevant Topics

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...

Muscular Dystrophy
Muscular dystrophy is a group of degenerative inherited disorders causing muscle weakness and loss of muscle tissue. The different types are Becker muscular dystrophy, Duchenne muscular dystrophy, Emery-Dreifuss muscular dystrophy, Facioscapulohumeral mu...